Insilico Medicine uses AI to discover novel SIK2 inhibitors

Insilico Medicine (“Insilico”), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the application of multiple generative AI models and AlphaFold structures for drug discovery.

FDA offers new guidelines for Covid-19 vaccine

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Today, we talk

June 17, 2024

GSK says long-acting asthma hopeful significantly cut attacks

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 10, 2024

LincRNA discovery could lead to targeted treatments

Our genetic code includes more than 15,000 specific sections that can be made into molecules called lincRNAs. Some of these sections can occur in coiled-up

April 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.